<?xml version="1.0" encoding="UTF-8"?>
<ref id="B62-pharmaceuticals-12-00101">
 <label>62.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Eyer</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Zouharova</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Sirmarova</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Fojtikova</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Stefanik</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Haviernik</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Nencka</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>de Clercq</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Ruzek</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses</article-title>
  <source>Antivir. Res.</source>
  <year>2017</year>
  <volume>142</volume>
  <fpage>63</fpage>
  <lpage>67</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.03.012</pub-id>
  <pub-id pub-id-type="pmid">28336346</pub-id>
 </element-citation>
</ref>
